{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:16:10Z","timestamp":1787066170110,"version":"build-2736575974"},"reference-count":45,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.3892\/etm.2015.2489","type":"journal-article","created":{"date-parts":[[2015,5,12]],"date-time":"2015-05-12T03:33:14Z","timestamp":1431401594000},"page":"379-385","source":"Crossref","is-referenced-by-count":8,"title":["Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer"],"prefix":"10.3892","volume":"10","author":[{"given":"JUN","family":"LIU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YANG","family":"XIAO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WEI","family":"WEI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JIAN-XIONG","family":"GUO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YANG-CHEN","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XIAO-HONG","family":"HUANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RONG-XIA","family":"ZHANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YI-JIA","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUAN","family":"ZHOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2015,5,12]]},"reference":[{"key":"key20180108124608_b1-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000264615","article-title":"Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine - case report","volume":"33","author":"Vrdoljak","year":"2010","journal-title":"Onkologie"},{"key":"key20180108124608_b2-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/00313020802563510","article-title":"Triple-negative\/basal-like breast cancer: Review","volume":"41","author":"Rakha","year":"2009","journal-title":"Pathology"},{"key":"key20180108124608_b3-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0b013e31825d5317","article-title":"Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients. A prospective, open, and unicentric Phase II clinical trial","volume":"36","author":"Fei","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"key20180108124608_b4-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.breast.2010.03.026","article-title":"Management of triple negative breast cancer","volume":"19","author":"Oakman","year":"2010","journal-title":"Breast"},{"key":"key20180108124608_b5-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s10549-007-9756-8","article-title":"Triple negative breast cancer: Molecular profiling and prognostic impact in adjuvant anthracycline-treated patients","volume":"111","author":"Tan","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"key20180108124608_b6-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3892\/ol.2012.1093","article-title":"Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis","volume":"5","author":"Liu","year":"2013","journal-title":"Oncol Lett"},{"key":"key20180108124608_b7-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.bjc.6602572","article-title":"Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF","volume":"92","author":"Sumpter","year":"2005","journal-title":"Br J Cancer"},{"key":"key20180108124608_b8-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s12032-010-9594-0","article-title":"S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: A meta-analysis","volume":"28","author":"Huang","year":"2011","journal-title":"Med Oncol"},{"key":"key20180108124608_b9-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000322371","article-title":"Efficacy and safety of S-1 in patients with metastatic breast cancer: Retrospective review in a single institution","volume":"79","author":"Hara","year":"2010","journal-title":"Oncology"},{"key":"key20180108124608_b10-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"key20180108124608_b11-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"key20180108124608_b12-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"key20180108124608_b13-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/548.6505","article-title":"Triple-negative breast cancer: Current state of the art","volume":"96","author":"Rastelli","year":"2010","journal-title":"Tumori"},{"key":"key20180108124608_b14-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"key20180108124608_b15-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1524-4741.2011.01175.x","article-title":"The paradox of triple negative breast cancer: Novel approaches to treatment","volume":"18","author":"Fornier","year":"2012","journal-title":"Breast J"},{"key":"key20180108124608_b16-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S0305-7372(10)70025-6","article-title":"Treatment of triple negative breast cancer (TNBC): Current options and future perspectives","volume":"36","author":"De Laurentiis","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"key20180108124608_b17-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"key20180108124608_b18-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1471-2407-8-307","article-title":"The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer","volume":"8","author":"Rhee","year":"2008","journal-title":"BMC Cancer"},{"key":"key20180108124608_b19-etm-0-0-2489","first-page":"2505","article-title":"Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer","volume":"61","author":"Geisler","year":"2001","journal-title":"Cancer Res"},{"key":"key20180108124608_b20-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1158\/1535-7163.MCT-13-0157","article-title":"Chk1\/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53","volume":"12","author":"Gadhikar","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"key20180108124608_b21-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1245\/s10434-009-0889-3","article-title":"p53 as a marker of prognosis in African-American women with breast cancer","volume":"17","author":"Dookeran","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"key20180108124608_b22-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jjco\/hyp007","article-title":"p53 as a specific prognostic factor in triple-negative breast cancer","volume":"39","author":"Chae","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108124608_b23-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.2010.32.1877","article-title":"Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer","volume":"29","author":"Hernandez-Aya","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180108124608_b24-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-008-9931-6","article-title":"HER-2\/neu expression in primary and metastatic breast cancer","volume":"113","author":"Lower","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key20180108124608_b25-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10549-004-2756-z","article-title":"Impact of metastatic estrogen receptor and progesterone receptor status on survival","volume":"90","author":"Lower","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"key20180108124608_b26-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJM197806012982203","article-title":"The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer","volume":"298","author":"Lippman","year":"1978","journal-title":"N Engl J Med"},{"key":"key20180108124608_b27-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2407-7-203","article-title":"Prognostic impact of clinicopathologic parameters in stage II\/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: Paradoxical features of the triple negative breast cancer","volume":"7","author":"Keam","year":"2007","journal-title":"BMC Cancer"},{"key":"key20180108124608_b28-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/COC.0b013e318256f619","article-title":"A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338","volume":"36","author":"Roy","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"key20180108124608_b29-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10549-014-3033-4","article-title":"Platinum-based chemotherapy in triple-negative advanced breast cancer","volume":"146","author":"Villarreal-Garza","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"key20180108124608_b30-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/annonc\/mdn395","article-title":"Platinum-based chemotherapy in triple-negative breast cancer","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"key":"key20180108124608_b31-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/CAD.0b013e328355076f","article-title":"Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines","volume":"23","author":"Virag","year":"2012","journal-title":"Anticancer Drugs"},{"key":"key20180108124608_b32-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1005800520747","article-title":"Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines","volume":"15","author":"Dunn","year":"1997","journal-title":"Invest New Drugs"},{"key":"key20180108124608_b33-etm-0-0-2489","first-page":"527","article-title":"Efficacy of docetaxel combined with oxaliplatin by different administration routes in treatment of anthracycline-resistant metastatic breast cancer","volume":"12","author":"Kang","year":"2005","journal-title":"Zhong Guo Zhong Liu Lin Chuang Yu Kang Fu"},{"key":"key20180108124608_b34-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00001813-200308000-00007","article-title":"Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: A preliminary phase II study","volume":"14","author":"Thuss-Patience","year":"2003","journal-title":"Anticancer Drugs"},{"key":"key20180108124608_b35-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-fu metabolism in cancer and orally-administrable 5-fu drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers (Basel)"},{"key":"key20180108124608_b36-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.bjc.6604536","article-title":"A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer","volume":"99","author":"Lee","year":"2008","journal-title":"Br J Cancer"},{"key":"key20180108124608_b37-etm-0-0-2489","first-page":"692","article-title":"Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer","volume":"26","author":"Lv","year":"2014","journal-title":"Chin J Cancer Res"},{"key":"key20180108124608_b38-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1634\/theoncologist.11-90001-42","article-title":"The role of capecitabine in first-line treatment for patients with metastatic breast cancer","volume":"11","author":"Gelmon","year":"2006","journal-title":"Oncologist"},{"key":"key20180108124608_b39-etm-0-0-2489","first-page":"855","article-title":"New oral anticancer drug, TS-1 (S-1) - from bench to clinic","volume":"28","author":"Shirasaka","year":"2001","journal-title":"Gan To Kagaku Ryoho"},{"key":"key20180108124608_b40-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol"},{"key":"key20180108124608_b41-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s10147-008-0784-0","article-title":"Gastrointestinal Oncology Study Group of Japan Clinical Oncology Group: Chemotherapy for metastatic disease: Review from JCOG trials","volume":"13","author":"Boku","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"key20180108124608_b42-etm-0-0-2489","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jjco\/hyn001","article-title":"Clinical efficacy of S-1 in pretreated metastatic breast cancer patients","volume":"38","author":"Shien","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"key20180108124608_b43-etm-0-0-2489","first-page":"3827","article-title":"Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial","volume":"30","author":"Yamamoto","year":"2010","journal-title":"Anticancer Res"},{"key":"key20180108124608_b44-etm-0-0-2489","first-page":"1467","article-title":"Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer","volume":"38","author":"Fujii","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"key20180108124608_b45-etm-0-0-2489","first-page":"202","article-title":"Clinical benefit of S-1 in metastatic breast cancer","volume":"33","author":"Saeki","year":"2006","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2015.2489\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T19:59:19Z","timestamp":1566676759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2015.2489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,12]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,5,12]]},"published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.3892\/etm.2015.2489"],"URL":"https:\/\/doi.org\/10.3892\/etm.2015.2489","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,12]]}}}